U.S. Justice Department Reclassifies State-Licensed Medical Marijuana as Schedule III Drug

2026-04-23

The BareStory

Acting Attorney General Todd Blanche signed an order on Thursday reclassifying state-licensed and federally approved medical marijuana from a Schedule I to a Schedule III controlled substance. The shift moves the drug from a category reserved for substances with a high potential for abuse to one with fewer restrictions and recognized medical applications.

The Department of Justice stated the reclassification is intended to facilitate scientific research into the safety and efficacy of the drug, while providing clarity and expanding treatment access for patients. The policy change does not legalize marijuana at the federal level for nationwide recreational use or alter current incarceration statuses. However, the adjustment is expected to ease regulatory and financial constraints on the cannabis industry, notably allowing state-licensed businesses to deduct standard operational expenses under federal tax codes.

While the current order applies specifically to state-licensed and approved medical products, the Justice Department plans to hold an expedited hearing in June to evaluate the formal, broader rescheduling of all marijuana at the federal level.

The marijuana policy update follows a separate executive order recently signed by President Donald Trump. That directive aims to accelerate the regulatory review, clinical research, and medical access for therapeutic psychedelic treatments—including psilocybin, MDMA, and ibogaine—with a particular focus on addressing trauma and mental health conditions among military veterans.

Left Perspective

Validating Suppressed Therapeutic Science
Failure on Restorative Justice
Engine for Corporate Consolidation

Right Perspective

Preserving Institutional Authority
Engine for Market Compliance
Targeted Therapeutic Pragmatism

Left Perspective

• Validating Suppressed Therapeutic Science Values the destigmatization of marginalized alternative medicines to treat vulnerable populations. Relocating state-licensed medical marijuana to Schedule III and advancing clinical research on psychedelics like MDMA and psilocybin acknowledges decades of suppressed medical science. This policy pivot officially recognizes the empirical efficacy of these substances in treating trauma, directly serving at-risk groups like military veterans who have exhausted conventional medical options.

• Failure on Restorative Justice Prioritizes systemic reform and repairing the historical damages inflicted by the War on Drugs. By explicitly refusing to alter current incarceration statuses or enact federal recreational legalization, this directive is viewed as an inadequate, inherently flawed half-measure. The framework preserves a punitive criminal justice system that continues to disproportionately punish vulnerable individuals for the exact same substance now legitimized for state-approved medical applications.

• Engine for Corporate Consolidation Fears the institutionalization of a profit-driven regulatory model that completely bypasses genuine social equity. The immediate material impact of this reclassification—allowing state-licensed businesses to deduct operational expenses under federal tax codes—caters heavily to established corporate stakeholders rather than harmed communities. There is deep concern that the expedited June hearing will prioritize market consolidation and financial protections for industry operators while ignoring the civil liberties of the broader public.

Right Perspective

• Preserving Institutional Authority Values the measured, orderly integration of new realities without dismantling overarching legal frameworks. Downgrading medical marijuana to Schedule III rather than enacting total de-scheduling ensures the substance remains subject to stringent federal oversight and medical gatekeeping. By specifically rejecting nationwide recreational legalization, this approach prevents the societal disruption associated with unchecked drug permissiveness while maintaining respect for the rule of law.

• Engine for Market Compliance Prioritizes resolving legal friction between existing state enterprises and overriding federal mandates. Permitting state-licensed cannabis businesses to utilize standard operational tax deductions eliminates a bureaucratic contradiction that penalized legally compliant, state-approved businesses. This logic values a rationalized tax code that brings existing economic activity out of a legal gray area and forces it into a formalized, tightly regulated market structure.

• Targeted Therapeutic Pragmatism Values civic duty and the overriding national obligation to care for those who serve the state. The targeted push for psychedelic research—specifically fast-tracking psilocybin, MDMA, and ibogaine—is framed not as a cultural liberalization, but as an urgent, strategic necessity to treat military trauma. The core objective is to harness tightly controlled scientific innovation to restore the mental health, functionality, and stability of the armed forces constituency.

How it may affect me

As a U.S. reader:

• Patients and military veterans may experience expanded long-term access to medical marijuana and therapeutic psychedelics for mental health conditions as federal barriers to clinical research and treatment applications are reduced.

• Individuals currently incarcerated for marijuana offenses will see no short-term changes to their legal status, as the reclassification does not legalize nationwide recreational use or alter existing criminal penalties.

• Consumers and workers interacting with state-licensed cannabis businesses may see market consolidation, as companies can now claim federal tax deductions for operational expenses, a move expected to financially strengthen established operators.

• The public may witness additional federal drug policy shifts in the near future depending on the outcome of a scheduled June hearing that will evaluate the broader rescheduling of all marijuana.

U.S. Justice Department Reclassifies State-Licensed Medical Marijuana as Schedule III Drug

The BareStory

Left Perspective

Right Perspective

How it may affect me

Read the story at